[go: up one dir, main page]

MX9405290A - Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen. - Google Patents

Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.

Info

Publication number
MX9405290A
MX9405290A MX9405290A MX9405290A MX9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A MX 9405290 A MX9405290 A MX 9405290A
Authority
MX
Mexico
Prior art keywords
group
piperazine
medicines
derivatives
salts
Prior art date
Application number
MX9405290A
Other languages
English (en)
Inventor
Hitoshi Tone
Masatoshi Morisue
Katsumi Tamura
Toshiki Miyazaki
Yoshimasa Nakano
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX9405290A publication Critical patent/MX9405290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Un objetivo de la presente invención es proporcionar un derivado depiperazina y sal del mismo que tiene efecto inhibitorio contra radicalessuperóxido (O2-). El derivado de piperazina de la presente invención estárepresentado por la fórmula general: ( en donde R1 es un grupo alquiloinferior; R2 es un grupo fenilalquilo inferior que puede tener de 1 a 3sustituyentes, en el anillo fenilo, seleccionados del grupo que consistede un grupo hidroxilo, un grupo fenilalcoxi inferior, un grupo alquiloinferior, un grupo alcoxi inferior y un átomo de halógeno; R3 es un átomode hidrógeno, un grupo alquilo inferior o un grupo fenilalquilo inferior;y R4 es un grupo hidroxilo, un grupo fenilalcoxi inferior o un grupotetrahidropiraniloxi).
MX9405290A 1993-07-13 1994-07-12 Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen. MX9405290A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5172780A JPH0725858A (ja) 1993-07-13 1993-07-13 ピペラジン誘導体

Publications (1)

Publication Number Publication Date
MX9405290A true MX9405290A (es) 1995-01-31

Family

ID=15948218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9405290A MX9405290A (es) 1993-07-13 1994-07-12 Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.

Country Status (10)

Country Link
US (1) US5607934A (es)
EP (1) EP0659182A1 (es)
JP (1) JPH0725858A (es)
KR (1) KR950703554A (es)
CN (1) CN1112364A (es)
AU (1) AU676584B2 (es)
CA (1) CA2143203A1 (es)
MX (1) MX9405290A (es)
PH (1) PH31162A (es)
WO (1) WO1995002593A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006826A (es) * 2000-01-18 2004-04-05 Nereus Phamraceuticals Inc Un inhibidor de division celular y un metodo de produccion del mismo.
CZ2003182A3 (cs) * 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
KR101184374B1 (ko) * 2002-08-02 2012-09-20 니리어스 파마슈티컬즈, 인코퍼레이션 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성 방법
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2595636A4 (en) 2010-07-22 2014-01-15 Reven Pharmaceuticals Inc METHOD FOR TREATING OR DISABLING DISEASES AND INCREASING PERFORMANCE BY USING SOLUTION THAT IS SOLVED BY MAGNETIC DIPOLE
CN101935306B (zh) * 2010-07-22 2013-12-25 沈阳药科大学 二酮哌嗪类衍生物及其应用
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
CA2978679A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
IL263439B1 (en) 2016-06-06 2025-02-01 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
SG11201907023UA (en) 2017-02-01 2019-08-27 Beyondspring Pharmaceuticals Inc Method of reducing neutropenia
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009380A1 (en) * 1989-02-10 1990-08-23 Otsuka Pharmaceutical Co., Ltd. Indole derivatives, preparation thereof, and drug for preventing and treating nephritis containing same

Also Published As

Publication number Publication date
PH31162A (en) 1998-03-20
AU7083294A (en) 1995-02-13
AU676584B2 (en) 1997-03-13
CA2143203A1 (en) 1995-01-26
US5607934A (en) 1997-03-04
WO1995002593A1 (en) 1995-01-26
CN1112364A (zh) 1995-11-22
EP0659182A1 (en) 1995-06-28
KR950703554A (ko) 1995-09-20
JPH0725858A (ja) 1995-01-27

Similar Documents

Publication Publication Date Title
MX9405290A (es) Derivados de piperazina y sales de los mismos, proceso para su preparaciony medicamentos que los contienen.
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
BR9612099A (pt) Processo para preparar um composto derivado de piperidina, regioisÈmero, processo para preparar um regioisÈmero, derivado de ácido 4-( alfa,alfa, di-substuìdo) toluico e 4- (alfa, alfa-di-não substitìdo) toluico.
AR245447A1 (es) Procedimiento para preparar derivados de 2,4-diamino-5-(biciclo-sustituido)metilpirimidinas.
AR024390A1 (es) Nuevos compuestos
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
MX9203899A (es) Derivados de hidrazina, composicion farmaceutica que los contiene y procedimiento para obtener dichos derivados.
YU19494A (sh) Derivati cefalosporina
CO4840509A1 (es) 2,4 diaminopirimidinas sustituidas, medicamento que contiene dichos compuestos para el control o la prevencion de enfermedades infecciosas y procedimiento para la preparacion de dichos compuestos"
ES8801617A1 (es) Un procedimiento para preparar derivados de arilciclobutilalquilamina
MX9306227A (es) Nuevos derivados de taxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
HU906360D0 (en) Process for producing quinoline derivatives and pharmaceutical preparatives containing such compounds
ATE40358T1 (de) 2,3-dihydrobenzofuran-derivate, mehrere verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
ES2058177T3 (es) Nuevos derivados de alcanosulfonanilida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
AR009266A1 (es) Un derivado de aciloamino alquenilen-amida, un proceso para su preparacion y una composicion farmaceutica que lo comprende
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
DE69617909D1 (de) 2-substituierte vitamin-d3-derivate
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
ES2063117T3 (es) Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CO4520266A1 (es) Derivado de 1,3-oxazin-4-ona, el herbicida que lo contiene y los productos intermedios para prepararlo
ES2086442T3 (es) Derivados de fluoroetilcamptotecina.
ES2038166T3 (es) Procedimiento para preparar un derivado de indenotiazol.
BR0214139A (pt) Derivados de fenil-propargil éter